Feasibility of Superior Rectal Artery Embolization for the Treatment of Hemorrhoidal Disease (EMBORRHOID)

With an estimated prevalence between 4 and 35%, the hemorrhoidal disease is the most frequent proctologic disease. Its symptoms are mainly rectorrhagia, externalization of the hemorrhoidal cushions (muco-hemorrhoidal prolapse), and/or pain and pruritus. Its acute complications (external and/or internal thromboses) are unpredictable.

Surgical treatment concerns approximately 10% of patients with diagnosed hemorrhoidal pathologies. The elective ligature of the arteria haemorrhoidalis under trans-anal Doppler scanning was developed in order to reduce the postoperative morbidity of hemorrhoidal surgery. This technique consists in a ligation of the superior rectal artery under Doppler control in order to decrease the blood flow within the hemorrhoids and therefore to reduce them. It is effective in the treatment of internal hemorrhoidal pathology without prolapse (grade II). The complications rate is low and estimated between 2 and 12% : rectorrhagia (4.3%), thrombosed hemorrhoids (1,8%), fissure (0,8%), acute urine retention (0,7%).

With the major advances in interventional radiology such ligation could be performed by an endovascular coil embolization. Until now no direct study exists on the subject but several case reports show the feasibility of an embolization of the superior rectal arteries for rectorrhagia of various etiologies such as the hemorrhoidal disease.

Endovascular access should increase the selectivity of the embolization compared to the Doppler scanning technique. Indeed the arteriography makes it possible to scan all branches of the superior rectal artery and therefore to occlude permanently the branches that feed the hemorrhoidal plexuses. Moreover the endovascular embolization technique should avoid the main complications of the trans-anal access technique.

The primary objective of this study is : the assessment of the efficacy of endovascular coil embolization of the superior rectal arteries in the management of the symptoms of the hemorrhoidal disease grade II and III. The secondary objective is : the assessment of postoperative complications.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

26

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Marseille
      • Marseille, Marseille, France, 13005
        • Assistance Publique Hopitaux de Marseille

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Suffering from a symptomatic hemorrhoidal disease stage II or III (history of prior medical treatment or instrumental do not prohibit the inclusion in the study)
  • Patient agreeing to participate in the study and who signed an informed consent
  • Patient willing to lend to post-operative monitoring for a year
  • Patient assured social

Exclusion Criteria:

  • Diseases and colorectal proctologic / History proctologic
  • Acute Complication hemorrhoidal disease course (thrombosis)
  • History of proctology surgery for hemorrhoidal disease
  • Anal stenosis congenital or acquired
  • Chronic anal fissure, anal suppuration associated
  • Chronic Inflammatory Bowel Disease
  • History of colorectal cancer
  • History of rectal resection and / or sigmoid
  • Rectal prolapse
  • Comorbidities
  • Portal hypertension
  • Severe atherosclerotic pathology (significant stenosis in aorto-iliac-femoral artery or branches for visceral).
  • General Affection responsible for a disorder of hemostasis objective (hemophilia, von Willebrand disease thrombocytopenia) and anticoagulants.
  • Psychiatric disorder making it impossible informed of and / or postoperative care
  • Neurological disease directly or indirectly involving the rectosphinctérienne motor (multiple sclerosis, spinal cord injury or nerve root, polyneuropathy).
  • Patients whose condition appears too insecure or taking steroids or immunosuppressive leading to an unacceptable surgical risk.
  • Background
  • Pregnancy declared (the existence of effective contraception will be checked for women of childbearing age)
  • Major Trust
  • Patients who do not speak French, refusing or unfit for monitoring proposed in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: coils

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Decrease of the felt pain
Time Frame: 26 MONTHS
It will be expected a decrease of the felt pain at least of 2 points measured by visual analog scale for patients treated by coil embolization
26 MONTHS

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reaaparition or obstinacy of the hemorroidal symptoms
Time Frame: 26 months
Reaaparition or obstinacy of the symptoms will be assess by clinical exam at 1,3,6 and 12 months
26 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: vincent vidal, Assistance Publique Hopitaux de Marseille
  • Study Director: Urielle DESALBRES, Assistance Publique Hopitaux de Marseille

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 14, 2014

Primary Completion (Actual)

April 1, 2017

Study Completion (Actual)

June 30, 2018

Study Registration Dates

First Submitted

November 19, 2014

First Submitted That Met QC Criteria

November 25, 2014

First Posted (Estimated)

December 1, 2014

Study Record Updates

Last Update Posted (Actual)

May 8, 2026

Last Update Submitted That Met QC Criteria

May 4, 2026

Last Verified

August 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • 2013-41

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hemorrhoidal Disease

Clinical Trials on NESTER COILS

Subscribe